These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26863111)

  • 1. Serum angiogenic profile in abnormal placentation.
    Biberoglu E; Kirbas A; Daglar K; Biberoglu K; Timur H; Demirtas C; Karabulut E; Danisman N
    J Matern Fetal Neonatal Med; 2016 Oct; 29(19):3193-7. PubMed ID: 26863111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio.
    Zhang F; Gu M; Chen P; Wan S; Zhou Q; Lu Y; Li L
    Placenta; 2022 Jun; 124():48-54. PubMed ID: 35635854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta.
    Uyanıkoğlu H; İncebıyık A; Turp AB; Çakmak G; Sak S; Hilali NG
    Balkan Med J; 2018 Jan; 35(1):55-60. PubMed ID: 28903888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast.
    Wehrum MJ; Buhimschi IA; Salafia C; Thung S; Bahtiyar MO; Werner EF; Campbell KH; Laky C; Sfakianaki AK; Zhao G; Funai EF; Buhimschi CS
    Am J Obstet Gynecol; 2011 May; 204(5):411.e1-411.e11. PubMed ID: 21316642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum.
    Faraji A; Akbarzadeh-Jahromi M; Bahrami S; Gharamani S; Raeisi Shahraki H; Kasraeian M; Vafaei H; Zare M; Asadi N
    J Obstet Gynaecol; 2022 Jul; 42(5):900-905. PubMed ID: 34558384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis on the roles of angiogenesis-related factors including serum vitamin D, soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt1), and vascular endothelial growth factor (VEGF) in the diagnosis and severity of late-onset preeclampsia.
    Cim N; Kurdoglu M; Ege S; Yoruk I; Yaman G; Yildizhan R
    J Matern Fetal Neonatal Med; 2017 Jul; 30(13):1602-1607. PubMed ID: 27658884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
    Govender N; Naicker T; Rajakumar A; Moodley J
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?
    Bdolah Y; Lam C; Rajakumar A; Shivalingappa V; Mutter W; Sachs BP; Lim KH; Bdolah-Abram T; Epstein FH; Karumanchi SA
    Am J Obstet Gynecol; 2008 Apr; 198(4):428.e1-6. PubMed ID: 18191808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
    Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE
    Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes.
    Salahuddin S; Wenger JB; Zhang D; Thadhani R; Karumanchi SA; Rana S
    Hypertens Pregnancy; 2016 Aug; 35(3):330-45. PubMed ID: 27028795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia.
    Wikström AK; Larsson A; Eriksson UJ; Nash P; Nordén-Lindeberg S; Olovsson M
    Obstet Gynecol; 2007 Jun; 109(6):1368-74. PubMed ID: 17540809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion-a pilot study.
    Samuel A; Bonanno C; Oliphant A; Batey A; Wright JD
    Prenat Diagn; 2013 Nov; 33(11):1050-3. PubMed ID: 23836321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete.
    Zhou J; Li J; Yan P; Ye YH; Peng W; Wang S; Wang XT
    Placenta; 2014 Sep; 35(9):691-5. PubMed ID: 25063251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating angiogenic factors and placental abruption.
    Signore C; Mills JL; Qian C; Yu K; Lam C; Epstein FH; Karumanchi SA; Levine RJ
    Obstet Gynecol; 2006 Aug; 108(2):338-44. PubMed ID: 16880304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa.
    Wang N; Shi D; Li N; Qi H
    Ann Med; 2021 Dec; 53(1):2041-2049. PubMed ID: 34927512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor.
    Shibata E; Rajakumar A; Powers RW; Larkin RW; Gilmour C; Bodnar LM; Crombleholme WR; Ness RB; Roberts JM; Hubel CA
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4895-903. PubMed ID: 15886253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein.
    Zelop C; Nadel A; Frigoletto FD; Pauker S; MacMillan M; Benacerraf BR
    Obstet Gynecol; 1992 Oct; 80(4):693-4. PubMed ID: 1383899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy.
    Palm M; Basu S; Larsson A; Wernroth L; Åkerud H; Axelsson O
    Acta Obstet Gynecol Scand; 2011 Nov; 90(11):1244-51. PubMed ID: 21568945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.